{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-143750","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.937815+00:00","generated_at":"2026-05-19T01:23:49.613476+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Atea shareholders elect three Class II directors, ratify KPMG, approve executive compensation","bullets":["Bruno Lucidi, Polly Murphy, and Bruce Polsky elected as Class II directors to 2028 term.","Ratification of KPMG as independent auditor for FY2025 approved with 73.8M votes for.","Advisory (non-binding) approval of named executive officer compensation received 46.5M votes for.","Approximately 87.6% of outstanding shares represented at June 20, 2025 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-143750","json":"https://secwatch.observer/filing/0001193125-25-143750.json","markdown":"https://secwatch.observer/filing/0001193125-25-143750.md","text":"https://secwatch.observer/filing/0001193125-25-143750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525143750/0001193125-25-143750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525143750/d936449d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:23:49.613476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}